Q/C Technologies, Inc. (QCLS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Q/C Technologies, Inc. (QCLS) has a cash flow conversion efficiency ratio of -0.139x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.29 Million) by net assets ($23.69 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Q/C Technologies, Inc. fund operations to measure how many days the company can operate on defensive assets alone.
Q/C Technologies, Inc. - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Q/C Technologies, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Q/C Technologies, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Q/C Technologies, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pasdec Holdings Bhd
KLSE:6912
|
-0.022x |
|
Heramed Ltd
AU:HMD
|
-3.359x |
|
Seoam Machinery Industry Co.Ltd
KQ:100660
|
-0.021x |
|
Mustang Industrial
TWO:5460
|
0.024x |
|
Smart Logistics Global Limited Ordinary Shares
NASDAQ:SLGB
|
-0.051x |
|
ATOME ENERGY PLC LS-002
F:J6J
|
N/A |
|
Ant Precision Industry Co Ltd
TWO:3646
|
0.003x |
|
Tysnes Sparebank
OL:TYSB
|
N/A |
Annual Cash Flow Conversion Efficiency for Q/C Technologies, Inc. (2020–2025)
The table below shows the annual cash flow conversion efficiency of Q/C Technologies, Inc. from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see QCLS market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $21.75 Million | $-9.07 Million | -0.417x | +31.66% |
| 2024-12-31 | $14.72 Million | $-8.98 Million | -0.610x | +39.99% |
| 2023-12-31 | $12.77 Million | $-12.98 Million | -1.016x | -21.70% |
| 2022-12-31 | $14.70 Million | $-12.27 Million | -0.835x | -1.17% |
| 2021-12-31 | $23.65 Million | $-19.52 Million | -0.825x | -136.38% |
| 2020-12-31 | $-5.26 Million | $-11.92 Million | 2.268x | -- |
About Q/C Technologies, Inc.
Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company. It operates through Pharmaceuticals and Computing Technology segments. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, … Read more